Picture courtesy The News Minute
New Delhi: The supply price of COVID-19 vaccine Covaxin to the Central government at Rs 150 per dose is not sustainable in the long run, Bharat Biotech said on Tuesday.
The Centre’s supplying price is pushing the pricing structure for the private sector upward, the vaccine maker said, justifying Covaxin’s higher price when compared to other COVID-19 vaccines available for the private sector in India.
According to the company, fundamental business reasons ranging from low procurement volumes, high distribution costs and retail margins among others were contributing to higher pricing of Covaxin.
“The supply price of Covaxin to the government of India at Rs 150 per dose is a non-competitive price and clearly not sustainable in the long run. Hence a higher price in private markets is required to offset part of the costs,” Bharat Biotech said in a statement.
New Delhi: The Centre on Monday scrapped the 'no-detention policy' for Class 5 and 8…
Bhubaneswar: In a hit and run case, seven persons including a woman were critically injured…
Bhubaneswar: The Odisha government is committed towards achieving 7.5 GW of solar energy by 2030…
Mumbai: Dharma Productions new social media post has left netizens speculating about a sequel to…
Bhubaneswar: Asma al-Assad, wife of ousted Syrian president Bashar al-Assad, has reportedly filed for divorce…
Cuttack: The second campus of SCB Medical College and Hospital in Cuttack would be completed…
This website uses cookies.